Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA1-64) in the rat heart

Regulatory Peptides

Volumn 165, Issue 1, 2010, Pages 78-85

  Angelone, Tommaso ^a   Quintieri, Anna Maria ^a   Goumon, Yannich ^b   Di Felice, Valentina ^c   Filice, Elisabetta ^a   Gattuso, Alfonsina ^a   Mazza, Rosa ^a   Corti, Angelo ^d   Tota, Bruno ^a   Metz Boutigue, Marie Hélène ^b   Cerra, Maria Carmela ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b U575 Insert   (France)

^c UNIVERSITY OF PALERMO   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiomyocytes; Cytoskeleton; Inotropy; Lusitropy; Rat CgA1 64; Rat Langendorff heart; Vasostatin

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN A [1-64]; CYTOCHALASIN D; PEPTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASOSTATIN 1; WORTMANNIN;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CELL FUNCTION; CONTROLLED STUDY; CYTOSKELETON; HEART CELL CULTURE; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE RELAXATION; INOTROPISM; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; WISTAR RAT;

ANIMALS; CELL LINE; CHROMOGRANIN A; CYTOSKELETON; HEART; HUMANS; MALE; MYOCYTES, CARDIAC; RATS; RATS, WISTAR;

RATTUS;

EID: 78649844974     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.10.003     Document Type: Article

References (47)

1. Helle K.B., Metz-Boutigue M.H., Aunis D. Chromogranin A as a calcium-binding precursor for a multitude of regulatory peptides for immune, endocrine and metabolic system. Curr Med Chem Imm Endoc Metab Agents 2001, 1:119-140.
2. Steiner H.J., Weiler R., Ludescher C., Schmid K.W., Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 1990, 38:845-850.
3. Pieroni M., Corti A., Tota B., Curnis F., Angelone T., Colombo B., Cerra M.C., Bellocci F., Crea F., Maseri A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007, 28:1117-1127.
4. Courel M., Rodemer C., Nguyen S.T., Pance A., Jackson A.P., O'connor D.T., Taupenot L. Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. J Biol Chem 2006, 281(49):38038-38051.
5. Glattard E., Angelone T., Strub J.M., Corti A., Aunis D., Tota B., Metz-Boutigue M.H., Goumon Y. Characterization of natural vasostatin-containing peptides in rat heart. FEBS 2006, 273:3311-3321.
6. Cerra M.C., De Iuri L., Angelone T., Corti A., Tota B. Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol 2006, 101:43-52.
7. Stridsberg M., Oberg K., Li Q., Engstrom U., Lundqvist G. () Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995, 144:49-59.
8. Nobels F.R., de Herder W.W., Kwekkeboom D.J., Coopmans W., Mulder A., Bouillon R., Lamberts S.W. () Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur J Endocrinol 1994, 131(6):589-593.
9. Hsiao R.J., Mezger M.S., O'Connor D.T. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990, 37(3):955-964.
10. Ceconi C., Ferrari R., Bachetti T., Opasich C., Volterrani M., Colombo B., Parrinello G., Corti A. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002, 23:967-974.
11. Estensen M.E., Hognestad A., Syversen U., Squire I., Ng L., Kjekshus J., Dickstein K., Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 2006, 152:927.e1-927.e6.
12. Mahapatra N.R., O'Connor D.T., Vaingankar S.M., Hikim A.P., Mahata M., Ray S., Staite E., Wu H., Gu Y., Dalton N., Kennedy B.P., Ziegler M.G., Ross J., Mahata S.K. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005, 115:1942-1952.
13. Tota B., Imbrogno S., Mannarino C., Mazza R. Vasostatins and negative inotropy in vertebrate hearts. Curr Med Chem 2004, 4:195-201.
14. Imbrogno S., Angelone T., Corti A., Adamo C., Helle K.B., Tota B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol 2004, 139:20-28.
15. Cappello S., Angelone T., Tota B., Pagliaro P., Penna C., Rastaldo R., Corti A., Losano G., Cerra M.C. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 2007, 293:H719-H727.
16. 1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J 2008, 22:3992-4004.
17. Malan D., Gallo M.P., Bedendi I., Biasin C., Levi R.C., Alloatti G. Microtubules mobility affects the modulation of L-type I(Ca) by muscarinic and beta-adrenergic agonists in guinea-pig cardiac myocytes. J Mol Cell Cardiol 2003, 35:195-206.
18. Da Costa S.R., Okamoto C.T., Hamm-Alvarez S.F. Actin microfilaments et al.-the many components, effectors and regulators of epithelial cell endocytosis. Adv Drug Deliv Rev 2003, 55:1359-1383.
19. Rogers S.L., Gelfand V.I. Membrane trafficking, organelle transport, and the cytoskeleton. Curr Opin Cell Biol 2000, 12:57-62.
20. Ferrero E., Scabin S., Magni E., Foglieni C., Belloni D., Colombo B., Curnis F., Villa A., Li C., Ferrero M.E., Corti A. Chromogranina A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 2004, 18:554-556.
21. Blois A., Srebro B., Mandalà M., Corti A., Helle K.B., Serck-Hanssen G. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept 2006, 135:78-84.
22. Blois A., Holmsen H., Martino G., Corti A., Metz-Boutigue M.H., Helle K.B. Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine. Regul Pept 2006, 134:30-37.
23. Mazza R., Mannarino C., Imbrogno S., Barbieri S.F., Adamo C., Angelone T., Corti A., Tota B. Crucial role of cytoskeleton reorganization in the negative inotropic effect of chromogranin A-derived peptides in eel and frog hearts. Regul Pept 2007, 138:145-151.
24. Angelone T., Goumon Y., Cerra M.C., Metz-Boutigue M.H., Aunis D., Tota B. The emerging cardioinhibitory role of the hippocampal cholinergic neurostimulating peptide. J Pharmacol Exp Ther 2006, 318:336-344.
25. Ratti S., Curnis F., Longhi R., Colombo B., Gasparri A., Magni F., Manera E., Metz-Boutigue M.H., Corti A. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem 2000, 275:29257-29263.
26. Atherton E, Sheppard RC. Solid phase peptide synthesis: a practical approach (Rickwood, D., and Hames, B. D., series eds.), IRL Press, Oxford, UK. 1989.
27. Angelone T., Quintieri A.M., Brar B.K., Limchaiyawat P.T., Tota B., Mahata S.K., Cerra M.C. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008, 149:4780-4793.
28. Calaghan S.C., White E., Bedut S., Le Guennec J.Y. Cytochalasin D reduces Ca2+ sensitivity and maximum tension via interactions with myofilaments in skinned rat cardiac myocytes. J Physiol 2000, 529:405-411.
29. Jacobshagen C., Kortlepel S., Unsoeld B.W., Sowa T., Koegler H., Hasenfuss G., Maier L.S. Inhibition of PI3K improves contractility in alpha1-adrenergically stimulated myocardium. Front Biosci 2008, 13:6841-6849.
30. Zimmermann N., Boknik P., Gams E., Gsell S., Jones L.R., Maas R., Neumann J. Scholz mechanisms of the contractile effects of 2, 3-butanedione-monoxime in the mammalian heart. Naunyn Schmiedebergs Arch Pharmacol 1996, 354(4):431-436.
31. Katoh S., Toyama J., Aoyama M., Miyamoto N., Seo H., Matsui N., Kodama I., Yamada K. Mechanisms of atrial natriuretic peptide (ANP) secretion by rat hearts perfused in vitro-Ca2(+)-dependent signal transduction for ANP release by mechanical stretch. Jpn Circ J 1990, 54(10):1283-1294.
32. Ehler E., Perriard J.C. Cardiomyocyte cytoskeleton and myofibrillogenesis in healthy and diseased heart. Heart Fail Rev 2000, 5:259-269.
33. Hoshijima M. Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. Am J Physiol Heart Circ Physiol 2006, 290:H1313-H1325.
34. Watson A.J., Levine S., Donowitz M., Montrose M.H. Serum regulates Na+/H+ exchange in Caco-2 cells by a mechanism which is dependent on F-actin. J Biol Chem 1992, 267:956-962.
35. Tesi C., Colomo F., Piroddi N., Poggesi C. Characterization of the cross-bridge force-generating step using inorganic phosphate and BDM in myofibrils from rabbit skeletal muscles. J Physiol 2002, 541:187-199.
36. Hong S.J., Chang C.C. (1998) Novel inhibition of contractility by wortmannin in skeletal muscle. Br J Pharmacol 1998, 124:849-856.
37. Adhikari B.B., Wang K. Interplay of troponin- and myosin-based pathways of calcium activation in skeletal and cardiac muscle: the use of W7 as an inhibitor of thin filament activation. Biophys J 2004, 86:359-370.
38. Goldblum S.E., Ding X., Campbell-Washington J. TNF-alpha induces endothelial cell F-actin depolymerization, new actin synthesis, and barrier dysfunction. Am J Physiol 1993, 264:C894-C905.
39. Brekke J.F., Osol G.J., Helle K.B. N-Terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries. Regul Pept 2002, 105:93-100.
40. 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen Comp Endocrinol 2004, 136:217-224.
41. Angeletti R.H., Aardal S., Serck-Hansen G., Gee P., Helle K.B. Vasoinhibitory activity of syntetic peptides from the amino terminus of chromogranin A. Acta Physiol Scand 1994, 152:11-19.
42. Russel J., Gee P., Liu S.M., Angeletti R.H. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 1994, 135:337-342.
43. 1-40) interacts with monolayer of membrane lipids of fungal and mammalian compositions. Ann N Y Acad Sci 2002, 971:352-354.
44. Lugardon K., Chasserot-Golaz S., Kieffer A.E., Maget-Dana R., Nullans G., Kieffer B., Aunis D., Metz-Boutigue M.H. Structural and biological characterization of chromofungin, the antifungal chromogranin A (47-66)-derived peptide. Ann N Y Acad Sci 2002, 971:359-361.
45. Tota B., Quintieri A.M., Di Felice V., Cerra M.C. New biological aspects of chromogranin A-derived peptides: focus on vasostatins. Comp Biochem Physiol A Mol Integr Physiol 2007, 147:11-18.
46. Di Felice V., Cappello F., Montalbano A., Ardizzone N., Campanella C., De Luca A., Amelio D., Tota B., Corti A., Zummo G. Human recombinant vasostatin-1 may interfere with cell-extracellular matrix interactions. Ann N Y Acad Sci 2006, 1090:305-310.
47. Upla P., Marjomaki V., Kankaanpaa P., Ivaska J., Hyypia T., Van Der Goot F.G., Heino J. Clustering induces a lateral redistribution of alpha 2 beta 1 integrin from membrane rafts to caveolae and subsequent protein kinase C-dependent internalization. Mol Biol Cell 2004, 15:625-636.